Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA MedGuide Distribution Guidance May Mean Little Change For Manufacturers

Executive Summary

FDA is demonstrating its intent to use discretion in enforcement with a draft guidance aimed at clarifying when Medication Guides must be distributed. However, as a practical matter, pharmaceutical manufacturers may still have to maintain their existing distribution systems for the guides.

Related Content

Final Guidance Clarifies Distribution Requirements For MedGuides
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
QOL Medical’s Sucraid Is First To Lose Its REMS
FDA To Sponsors: Say Goodbye To MedGuide-Only REMS
MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy
Early REMS Assessments Show Room For Improvement In MedGuides
PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS
FDA Seeks To Write MedGuides Outside REMS Process





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts